Home The Word Brain My Amedeo FAQ Privacy About


Hanzi Hunter

Learning 500 Chinese characters in 30 days is possible.

Abstract • About

  Neoplasms of the CNS

  Free Subscription


Articles published in J Neuropathol Exp Neurol

Retrieve available abstracts of 100 articles:
HTML format



Single Articles


    March 2026
  1. SPYRETOS C, Pardo Ladino JM, Andersen Blomstrand H, Nyman P, et al
    Quantification of Ki-67 labeling index in pediatric brain tumor immunohistochemistry images.
    J Neuropathol Exp Neurol. 2026 Mar 10:nlaf163. doi: 10.1093.
    PubMed     Abstract available


  2. EBNER BA, Ida CM, Kollmeyer TM, Jenkins RB, et al
    Association of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas.
    J Neuropathol Exp Neurol. 2026 Mar 9:nlag007. doi: 10.1093.
    PubMed     Abstract available


  3. COTY-FATTAL Z, Smith H, McCord M, Mejia-Bautista M, et al
    Rapid assessment of MGMT promoter methylation status by droplet digital polymerase chain reaction on intraoperative smear preparation: A proof-of-concept study.
    J Neuropathol Exp Neurol. 2026;85:280-284.
    PubMed     Abstract available


    February 2026
  4. NISHIDA N, Hata Y
    Sudden unexpected death associated with previously undiagnosed gliomas: A mechanism-based interpretation of three autopsy cases.
    J Neuropathol Exp Neurol. 2026 Feb 14:nlag006. doi: 10.1093.
    PubMed    


  5. GRAY MT, Cayrol R, May A, Skaugen JM, et al
    Gliomas with succinate dehydrogenase deficiency: A case series and brief review of the literature of oncometabolite-driven gliomagenesis.
    J Neuropathol Exp Neurol. 2026 Feb 4:nlag004. doi: 10.1093.
    PubMed     Abstract available


    January 2026
  6. YUAN J, Liu H, Wen J, Zhao Z, et al
    Cardiotrophin-like cytokine factor 1 regulated by Sry-related HMG-box transcription factor 9 promotes malignant behavior and immune evasion of glioblastoma multiforme.
    J Neuropathol Exp Neurol. 2026 Jan 19:nlaf161. doi: 10.1093.
    PubMed     Abstract available


  7. VOYLES C, Bellizzi AM, Lopes Abath Neto O
    Survival analysis of brain-invasive otherwise benign meningiomas in a single-institution cohort.
    J Neuropathol Exp Neurol. 2026 Jan 12:nlaf157. doi: 10.1093.
    PubMed    


    December 2025
  8. FUKUOKA K, Irikura T, Kanemura Y, Hirato J, et al
    Intratumoral heterogeneity of MYC status and methylation subtyping in group 3 medulloblastoma: A case report.
    J Neuropathol Exp Neurol. 2025 Dec 23:nlaf153. doi: 10.1093.
    PubMed    


  9. MAFFICINI A, Pigato F, Miele E, Patrizi S, et al
    Fumarate hydratase-mutant glioma with giant-cell histology, MSH6 mutation, and hypermutation.
    J Neuropathol Exp Neurol. 2025 Dec 9:nlaf142. doi: 10.1093.
    PubMed    


  10. CHIANG WY, Li X, Tanaka R, Chiang J, et al
    Activated signaling pathways and metabolic processes in disseminating myxoid glioneuronal tumors.
    J Neuropathol Exp Neurol. 2025;84:1106-1112.
    PubMed     Abstract available


    November 2025
  11. BELAKHOUA S, Lopez G, Dubey S, Rai S, et al
    RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications.
    J Neuropathol Exp Neurol. 2025 Nov 29:nlaf129. doi: 10.1093.
    PubMed     Abstract available


  12. BROECHNER A, Maier AD, Mirian C, Sahm F, et al
    Analysis of anatomical location, mitoses, and Ki-67 in 2608 meningiomas.
    J Neuropathol Exp Neurol. 2025 Nov 20:nlaf131. doi: 10.1093.
    PubMed     Abstract available


  13. WELCH RL, Fluss RS, Yokoda RT, Himes BT, et al
    Primary sporadic intracranial DICER1 mutant sarcoma with SSTR2 positivity in an adult patient mimicking anaplastic meningioma.
    J Neuropathol Exp Neurol. 2025 Nov 11:nlaf053. doi: 10.1093.
    PubMed    


  14. WENG M, Zhu X
    FOXM1/CENPI axis regulation of proline and arginine metabolism in glioblastoma cells.
    J Neuropathol Exp Neurol. 2025 Nov 4:nlaf121. doi: 10.1093.
    PubMed     Abstract available


    October 2025
  15. MANDARA MT, Giglia G, Benedetti G, Falzone C, et al
    Tumor-associated macrophages in feline meningiomas: Exploring their prognostic significance.
    J Neuropathol Exp Neurol. 2025 Oct 21:nlaf119. doi: 10.1093.
    PubMed     Abstract available


  16. MURAYI R, El-Abtah M, Ejikeme T, Xiao T, et al
    Validation of an immunohistochemistry-based molecular group stratification of intracranial meningiomas.
    J Neuropathol Exp Neurol. 2025 Oct 15:nlaf120. doi: 10.1093.
    PubMed     Abstract available


    September 2025
  17. GUO Y, Liu H, Gao Z, Zhou Z, et al
    Mitochondrial dysfunction and its impact on pyroptosis and ferroptosis cross talk in glioma cells.
    J Neuropathol Exp Neurol. 2025 Sep 17:nlaf099. doi: 10.1093.
    PubMed     Abstract available


  18. VOONG V, Beccari S, Hashemi E, Kriener B, et al
    3D spatial sampling to quantify morphologic heterogeneity in isocitrate dehydrogenase-wildtype glioblastoma.
    J Neuropathol Exp Neurol. 2025 Sep 3:nlaf101. doi: 10.1093.
    PubMed     Abstract available


    August 2025
  19. ZHANG Z, Guo X, Qi T, Wang C, et al
    METTL14/IGF2BP2-mediated m6A modification of PD-L1 promotes proliferation, metastasis, and immune escape in high-grade gliomas.
    J Neuropathol Exp Neurol. 2025 Aug 11:nlaf090. doi: 10.1093.
    PubMed     Abstract available


    July 2025
  20. HAO Z, Han Y, Bo Y, Cao L, et al
    Knocking down RFWD3 suppresses the growth and migration of glioblastoma cells by blocking G2/M cycle progression.
    J Neuropathol Exp Neurol. 2025 Jul 23:nlaf087. doi: 10.1093.
    PubMed     Abstract available


  21. LIECHTY B, Kim S, Dobri G, Schwartz TH, et al
    SSTR2 expression in neoplastic and normal anterior pituitary is impacted by age, sex, and hormonal status.
    J Neuropathol Exp Neurol. 2025;84:626-633.
    PubMed     Abstract available


  22. HARPER SD, Perryman T, Dudley LA, Prabhu AS, et al
    Molecular characterization of benign intracranial glioependymal and arachnoid cysts suggest heterogeneous mechanisms of action.
    J Neuropathol Exp Neurol. 2025;84:617-625.
    PubMed     Abstract available


  23. SIDDIQ Z, Gilani A, Ung TH, Kleinschmidt-DeMasters BK, et al
    Isocitrate dehydrogenase-mutant astrocytoma in persons aged 55 years and older: Survival differences versus the young.
    J Neuropathol Exp Neurol. 2025;84:611-616.
    PubMed     Abstract available


    June 2025
  24. LOCHNER RH, Powell SZ, Fung KM, Zhang YJ, et al
    FGFR1 fusions in genomically and epigenetically bona fide glioblastoma, IDH-wildtype.
    J Neuropathol Exp Neurol. 2025 Jun 12:nlaf068. doi: 10.1093.
    PubMed    


  25. TERRY M, Reis G, Pekmezci M, Phillips JJ, et al
    PAS+/PASD- intracytoplasmic glycogen is not specific for clear cell meningioma.
    J Neuropathol Exp Neurol. 2025 Jun 6:nlaf065. doi: 10.1093.
    PubMed    


    May 2025
  26. TOLLEFSEN SE, Meta R, Solheim O, Mjones P, et al
    Merlin immunoreactivity fails to predict neurofibromatosis type 2 mutations in human meningiomas.
    J Neuropathol Exp Neurol. 2025 May 30:nlaf058. doi: 10.1093.
    PubMed     Abstract available


  27. TAUZIEDE-ESPARIAT A, Rousseau A, Basset L, Saffroy R, et al
    A comparison of CDKN2A status in gliomas using different techniques: The loss of p16 as a surrogate marker.
    J Neuropathol Exp Neurol. 2025 May 30:nlaf062. doi: 10.1093.
    PubMed     Abstract available


  28. FURUTA T, Miyoshi H, Moritsubo M, Nakajima R, et al
    Biological role and clinicopathological significance of leucine-rich alpha-2 glycoprotein 1 in the glioblastoma microenvironment.
    J Neuropathol Exp Neurol. 2025 May 9:nlaf049. doi: 10.1093.
    PubMed     Abstract available


  29. ROBINS SM, Rosenblatt M, Bruce JN, Canoll P, et al
    Solitary fibrous tumor in the pineal region: A series of 5 cases and literature review.
    J Neuropathol Exp Neurol. 2025;84:379-390.
    PubMed     Abstract available


    April 2025
  30. COOK DJ, Decker PA, Hardcastle JJ, Kollmeyer TM, et al
    EGFR transcript variants: Potential diagnostic biomarker for glioblastoma, IDH-wildtype?
    J Neuropathol Exp Neurol. 2025 Apr 25:nlaf041. doi: 10.1093.
    PubMed    


  31. UGWUOWO U, Faust B, Tang H, DiStasio M, et al
    Adequate capture of spatial heterogeneity of Ki-67 proliferative index in meningiomas requires multiple tissue sections.
    J Neuropathol Exp Neurol. 2025 Apr 21:nlaf043. doi: 10.1093.
    PubMed    


  32. DONO A, Pichardo-Rojas D, Mendoza Mora L, Pichardo-Rojas PS, et al
    MTAP immunohistochemistry as a surrogate marker of CDKN2A loss in brain tumors: A meta-analysis and literature review.
    J Neuropathol Exp Neurol. 2025 Apr 18:nlaf033. doi: 10.1093.
    PubMed     Abstract available


  33. LI Y, Shen X, Zhang J, Xian X, et al
    Adult diffuse IDH-wildtype lower-grade gliomas with PDGFRA gain/amplification should be upgraded as glioblastoma.
    J Neuropathol Exp Neurol. 2025 Apr 16:nlaf039. doi: 10.1093.
    PubMed     Abstract available


  34. NGUYEN P, Yokoda RT, Hossain Q, Bederson JB, et al
    Solitary fibrous tumor-meningioma collision tumor with 18 years of follow-up.
    J Neuropathol Exp Neurol. 2025 Apr 11:nlaf037. doi: 10.1093.
    PubMed    


    February 2025
  35. MORENO-TORRES B, Manzano-Benito I, Cantero D, Romo A, et al
    Integrating molecular analyses with the 2021 WHO classification of adult pilocytic astrocytomas.
    J Neuropathol Exp Neurol. 2025;84:255-263.
    PubMed     Abstract available


    December 2024
  36. CHEN A, Hart SL, Lannon M, Hawkins C, et al
    Meningiomas in Rubinstein-Taybi syndrome: A case report and comprehensive review.
    J Neuropathol Exp Neurol. 2024 Dec 31:nlae135. doi: 10.1093.
    PubMed     Abstract available


  37. VIZCAINO MA, Giannini C, Vaubel RA, Nguyen AT, et al
    Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma.
    J Neuropathol Exp Neurol. 2024;83:1003-1009.
    PubMed     Abstract available


    November 2024
  38. GUO Y, Li Y, Su P, Yan M, et al
    Tumor microtubes: A new potential therapeutic target for high-grade gliomas.
    J Neuropathol Exp Neurol. 2024 Nov 19:nlae119. doi: 10.1093.
    PubMed     Abstract available


    October 2024
  39. SHEKARIAN T, Ritz MF, Hogan S, Martins TA, et al
    Multidimensional analysis of matched primary and recurrent glioblastoma identifies contributors to tumor recurrence influencing time to relapse.
    J Neuropathol Exp Neurol. 2024 Oct 18:nlae108. doi: 10.1093.
    PubMed     Abstract available


  40. CECCHI R, Guptil D, Haslett N, Hristov A, et al
    Primary CNS histiocytic sarcoma: Two case reports highlighting a novel MIGA2::BRAF gene fusion and genome-wide DNA methylation profiling results.
    J Neuropathol Exp Neurol. 2024;83:882-886.
    PubMed    


    September 2024
  41. OHARA K, Al Assaad M, McNulty SN, Alnajar H, et al
    Detection of rare and novel gene fusions in patients with diffuse glioma: An institutional retrospective study.
    J Neuropathol Exp Neurol. 2024 Sep 28:nlae105. doi: 10.1093.
    PubMed    


  42. REIMANN RR, Gramatzki D, Bink A, Hench J, et al
    Long survival in a patient with fumarate hydratase mutation-associated glioma.
    J Neuropathol Exp Neurol. 2024 Sep 16:nlae100. doi: 10.1093.
    PubMed    


  43. KLEINSCHMIDT-DEMASTERS BK
    Mixed pituitary adenoma/pituitary neuroendocrine tumor-gangliocytoma: Immunohistochemical insights.
    J Neuropathol Exp Neurol. 2024;83:708-721.
    PubMed     Abstract available


  44. FENG Y, Wong PJC, Fu M, Kong Y, et al
    The comprehensive morphological and molecular characteristics of lipoastrocytoma: A case report.
    J Neuropathol Exp Neurol. 2024;83:785-790.
    PubMed    


    August 2024
  45. WANG C, Han H, Cheng F, Wang H, et al
    Clinical significance and potential mechanism of AEBP1 in glioblastoma.
    J Neuropathol Exp Neurol. 2024 Aug 27:nlae091. doi: 10.1093.
    PubMed     Abstract available


  46. TIAN S, Xie G, Zhang H, Zuo F, et al
    A heritable form of SMARCE1-related meningiomas with clinical implications.
    J Neuropathol Exp Neurol. 2024 Aug 19:nlae080. doi: 10.1093.
    PubMed    


  47. MORRIS M, Ararat K, Cutshall H, Gokden M, et al
    SMARCA4-deficient central nervous system metastases: A case series and systematic review.
    J Neuropathol Exp Neurol. 2024;83:638-654.
    PubMed     Abstract available


  48. ABOUBAKR O, Senova S, Kauv P, Castel D, et al
    A non-midline unclassified glioneuronal tumor with H3K27M mutation enlarging the spectrum of CNS tumors H3K27ME3-altered.
    J Neuropathol Exp Neurol. 2024;83:701-705.
    PubMed    


    July 2024
  49. TANAKA Y, Natsumeda M, Ohashi M, Saito R, et al
    Primary spinal cord gliomas: Pathologic features associated with prognosis.
    J Neuropathol Exp Neurol. 2024 Jul 29:nlae084. doi: 10.1093.
    PubMed     Abstract available


  50. ALTURKUSTANI M, Walker AD, Castaneda EA, Cotter JA, et al
    Utility of OLIG2 immunostaining in pediatric brain tumors with embryonal morphology.
    J Neuropathol Exp Neurol. 2024 Jul 27:nlae082. doi: 10.1093.
    PubMed     Abstract available


  51. KANATHANAVANICH M, Koga S, Stone SL, Roth J, et al
    CTDSP2::GLI1 fusion in glioblastoma: A diagnostic challenge through tumor heterogeneity.
    J Neuropathol Exp Neurol. 2024 Jul 9:nlae073. doi: 10.1093.
    PubMed    


  52. LE MK, Tran NQV, Nguyen PT, Nguyen TA, et al
    Comprehensive analysis of distinct circadian clock subtypes of adult diffuse glioma and their associations with clinicopathological, genetic, and epigenetic profiles.
    J Neuropathol Exp Neurol. 2024 Jul 4:nlae055. doi: 10.1093.
    PubMed     Abstract available


  53. FENG K, Ye G, Wang H, Li S, et al
    Research on the mechanism of TWSG1 in the malignant progression of glioma cells and tumor-associated macrophage infiltration.
    J Neuropathol Exp Neurol. 2024 Jul 1:nlae067. doi: 10.1093.
    PubMed     Abstract available


    June 2024
  54. KISELJAK-VASSILIADES K, Lipe K, Turin CG, Fishbein L, et al
    E-cadherin expression and gene expression profiles in corticotroph pituitary neuroendocrine tumor subtypes.
    J Neuropathol Exp Neurol. 2024;83:586-595.
    PubMed     Abstract available


  55. PARKER M, Kazemi F, Krishnakumar A, Horowitz MA, et al
    Availability and utilization of molecular testing for primary central nervous system tumors among US hospitals.
    J Neuropathol Exp Neurol. 2024;83:579-585.
    PubMed     Abstract available


  56. ZSCHERNACK V, Thomas C, Schaub C, Kristiansen G, et al
    FH-mutant glioma displaying the epigenetic signature of IDH-mutant astrocytomas.
    J Neuropathol Exp Neurol. 2024 Jun 14:nlae064. doi: 10.1093.
    PubMed    


  57. LORETO PALACIO P, Pan X, Jones D, Otero JJ, et al
    Exploring a distinct FGFR2::DLG5 rearrangement in a low-grade neuroepithelial tumor: A case report and mini-review of protein fusions in brain tumors.
    J Neuropathol Exp Neurol. 2024 Jun 4:nlae040. doi: 10.1093.
    PubMed     Abstract available


    May 2024
  58. SHIBAHARA I, Nakashima T, Toyoda M, Inukai M, et al
    Evolving driver mutations in adult-onset SHH-medulloblastoma originated from radiological cerebellar abnormality.
    J Neuropathol Exp Neurol. 2024 May 29:nlae051. doi: 10.1093.
    PubMed    


  59. VIZCAINO MA, Giannini C, Lalich D, Nael A, et al
    Ganglioglioma with anaplastic/high-grade transformation: Histopathologic, molecular, and epigenetic characterization of 3 cases.
    J Neuropathol Exp Neurol. 2024;83:416-424.
    PubMed     Abstract available


    April 2024
  60. MACRAE CB, Grieco KC, Solomon IH
    Diagnostic yield of postmortem brain examination following premortem brain biopsy for neoplastic and nonneoplastic disease.
    J Neuropathol Exp Neurol. 2024;83:331-337.
    PubMed     Abstract available


  61. WILCOCK DM, Goold E, Zuromski LM, Davidson C, et al
    EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization.
    J Neuropathol Exp Neurol. 2024 Apr 11:nlae028. doi: 10.1093.
    PubMed     Abstract available


    March 2024
  62. KALTER JA, Yang RA, Toland A, Milla S, et al
    IDH-mutant astrocytoma arising from a demyelinating plaque in a child with X-linked adrenoleukodystrophy.
    J Neuropathol Exp Neurol. 2024;83:289-292.
    PubMed    


  63. NEWMAN J, Leelatian N, Liang J
    Characterization of pediatric non-hematopoietic tumor metastases to the central nervous system: A single institution review.
    J Neuropathol Exp Neurol. 2024;83:268-275.
    PubMed     Abstract available


  64. DONEV K, Sundararajan V, Johnson D, Balan J, et al
    Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
    J Neuropathol Exp Neurol. 2024 Mar 6:nlae018. doi: 10.1093.
    PubMed     Abstract available


    February 2024
  65. QI P, Yao QL, Lao IW, Ren M, et al
    A custom next-generation sequencing panel for 1p/19q codeletion and mutational analysis in gliomas.
    J Neuropathol Exp Neurol. 2024 Feb 26:nlae011. doi: 10.1093.
    PubMed     Abstract available


  66. KRAUSE KA, Woods JK, Golby AJ, Lee EQ, et al
    Progestin-associated meningiomatosis with unusual schwannoma-like morphology.
    J Neuropathol Exp Neurol. 2024 Feb 1:nlae008. doi: 10.1093.
    PubMed    


    January 2024
  67. XI S, Huang Q, Zeng J
    A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.
    J Neuropathol Exp Neurol. 2024;83:125-130.
    PubMed     Abstract available


  68. FENG Y, Xu H, Hu X, Zhang J, et al
    Heterogenous driving genetic events contribute to the dissemination of choroid plexus papilloma.
    J Neuropathol Exp Neurol. 2024;83:131-135.
    PubMed    


  69. MARIET C, Grill J, Ajlil Y, Castel D, et al
    "Hemispheric pilocytic astrocytoma" revisited: A comprehensive clinicopathological and molecular series emphasizing their overlap with other glioneuronal tumors.
    J Neuropathol Exp Neurol. 2024;83:115-124.
    PubMed     Abstract available


  70. ABOUBAKR O, Metais A, Doz F, Saffroy R, et al
    LEF-1 immunohistochemistry, a better diagnostic biomarker than beta-catenin for medulloblastoma, WNT-activated subtyping.
    J Neuropathol Exp Neurol. 2024 Jan 17:nlad104. doi: 10.1093.
    PubMed    


  71. GUBBIOTTI MA, Weinberg JS, Weathers SP, Dasgupta P, et al
    An incidental finding of a high-grade glioma with pleomorphic and pseudopapillary features (HPAP) with PBRM1 mutation.
    J Neuropathol Exp Neurol. 2024 Jan 2:nlad114. doi: 10.1093.
    PubMed    


    December 2023
  72. ROBINSON LJ, Goold E, Potter S, Quigley EP, et al
    A pleomorphic xanthoastrocytoma highlighting the morphological heterogeneity of this uncommon tumor.
    J Neuropathol Exp Neurol. 2023;83:61-64.
    PubMed    


  73. GUNDOGDU F, Babaoglu B, Soylemezoglu F
    Reliability assessment of methylthioadenosine phosphorylase immunohistochemistry as a surrogate biomarker for CDKN2A homozygous deletion in adult-type IDH-mutant diffuse gliomas.
    J Neuropathol Exp Neurol. 2023 Dec 18:nlad109. doi: 10.1093.
    PubMed     Abstract available


    November 2023
  74. GESTRICH C, Grieco K, Lidov HG, Baird LC, et al
    H3K27-altered diffuse midline gliomas with MAPK pathway alterations: Prognostic and therapeutic implications.
    J Neuropathol Exp Neurol. 2023 Nov 30:nlad103. doi: 10.1093.
    PubMed     Abstract available


  75. HUA Y, Youens KE, Castro E, Wang D, et al
    Autopsy findings in a 6-month-old infant with rhabdoid tumor predisposition syndrome 1: Case report with literature review.
    J Neuropathol Exp Neurol. 2023;82:1040-1043.
    PubMed    


  76. WHITE B, Filo J, Orrego-Gonzalez E, Schwartz SN, et al
    Synchronous contralateral low-grade oligodendroglioma and high-grade IDH-mutant astrocytoma.
    J Neuropathol Exp Neurol. 2023;82:1048-1050.
    PubMed    


  77. NUECHTERLEIN N, Shelbourn A, Cimino PJ
    Whole gain of chromosome 19, not co-gain of chromosomes 19 and 20, characterizes a class of glioblastomas with more favorable outcomes.
    J Neuropathol Exp Neurol. 2023 Nov 14:nlad092. doi: 10.1093.
    PubMed    


  78. BLUM N, Mirian C, Maier AD, Mathiesen TI, et al
    Translocator protein (TSPO) expression in neoplastic cells and tumor-associated macrophages in meningiomas.
    J Neuropathol Exp Neurol. 2023 Nov 11:nlad093. doi: 10.1093.
    PubMed     Abstract available


    October 2023
  79. NAZEM A, Lavezo J, Abdullaev Z, Aldape K, et al
    Diffuse hemispheric glioma with H3-3B G34R mutation: Expanding the spectrum of histone H3 genes in diffuse hemispheric glioma, H3 G34-mutant.
    J Neuropathol Exp Neurol. 2023 Oct 25:nlad089. doi: 10.1093.
    PubMed    


  80. ABOUBAKR O, Metais A, Hasty L, Saffroy R, et al
    Brainstem oligodendroglioma, IDH-mutant, and 1P/19Q-codeleted: A potential diagnostic pitfall.
    J Neuropathol Exp Neurol. 2023;82:958-962.
    PubMed    


  81. CAO C, Zhang L, Sorensen MD, Reifenberger G, et al
    D-2-hydroxyglutarate regulates human brain vascular endothelial cell proliferation and barrier function.
    J Neuropathol Exp Neurol. 2023;82:921-933.
    PubMed     Abstract available


  82. SHELBOURN A, Nuechterlein N, Parada CA, Eaton J, et al
    Validating MCM2 as a clinically relevant surrogate immunohistochemical marker for an aggressive meningioma molecular subtype.
    J Neuropathol Exp Neurol. 2023 Oct 13:nlad082. doi: 10.1093.
    PubMed    


  83. KOLEILAT A, Kumar V, Al Hmada Y, Milosevic D, et al
    Concurrent TERT promoter C228T and C250T mutations in diffuse gliomas: Rare occurrence of intratumoral heterogeneity.
    J Neuropathol Exp Neurol. 2023 Oct 9:nlad081. doi: 10.1093.
    PubMed    


    September 2023
  84. XU E, Stone SL, Zhong Y, Golenberg N, et al
    A novel ARIH1::BRAF fusion in a glioma.
    J Neuropathol Exp Neurol. 2023 Sep 23:nlad074. doi: 10.1093.
    PubMed    


  85. ZHANG Y, Huang H, Liu P, Xie Y, et al
    NFYB increases chemosensitivity in glioblastoma by promoting HDAC5-mediated transcriptional inhibition of SHMT2.
    J Neuropathol Exp Neurol. 2023 Sep 23:nlad073. doi: 10.1093.
    PubMed     Abstract available


  86. YOKODA RT, Cobb WS, Yong RL, Crary JF, et al
    CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.
    J Neuropathol Exp Neurol. 2023;82:845-852.
    PubMed     Abstract available


    June 2023
  87. GUBBIOTTI MA, Madsen PJ, Tucker AM, Abdullaev Z, et al
    ZFTA-fused supratentorial ependymoma with a novel fusion partner, DUX4.
    J Neuropathol Exp Neurol. 2023;82:668-671.
    PubMed    


  88. MAIER AD, Christiansen SN, Haslund-Vinding J, Krogager ME, et al
    DNA methylation profile of human dura and leptomeninges.
    J Neuropathol Exp Neurol. 2023;82:641-649.
    PubMed     Abstract available


  89. FUKUOKA K, Nakazawa A, Hirato J, Nobusawa S, et al
    An infantile pineal embryonal tumor showing pathological features of a CNS ganglioneuroblastoma and the methylation profiling of an atypical teratoid/rhabdoid tumor and SMARCA4 mutation.
    J Neuropathol Exp Neurol. 2023;82:664-667.
    PubMed    


  90. BROGGI G, Barresi V
    Assessment of CDKN2A/B homozygous deletion in gliomas: To FISH or not to FISH?
    J Neuropathol Exp Neurol. 2023 Jun 12:nlad045. doi: 10.1093.
    PubMed    


    May 2023
  91. LE MK, Vuong HG, Nguyen TTT, Kondo T, et al
    NAA10 overexpression dictates distinct epigenetic, genetic, and clinicopathological characteristics in adult gliomas.
    J Neuropathol Exp Neurol. 2023 May 30:nlad037. doi: 10.1093.
    PubMed     Abstract available


  92. LIU X, Zhao J, Wu Q, Wang L, et al
    ANKRD22 promotes glioma proliferation, migration, invasion, and epithelial-mesenchymal transition by upregulating E2F1-mediated MELK expression.
    J Neuropathol Exp Neurol. 2023 May 10:nlad034. doi: 10.1093.
    PubMed     Abstract available


    April 2023
  93. GUBBIOTTI MA, Dhillon KS, Harris J, Kothari S, et al
    An unusual case of metastatic diffuse midline glioma in an adult.
    J Neuropathol Exp Neurol. 2023 Apr 19:nlad032. doi: 10.1093.
    PubMed    


  94. YANG X, Ye Z, Zhang M, Ouyang Y, et al
    Tissue clearing to examine glioma complexity in 3 dimensions.
    J Neuropathol Exp Neurol. 2023 Apr 6:nlad024. doi: 10.1093.
    PubMed     Abstract available


    March 2023
  95. PERSONS JE, Eschbacher KL
    A case of dedifferentiated meningeal solitary fibrous tumor.
    J Neuropathol Exp Neurol. 2023;82:367-369.
    PubMed    


  96. CONG H, Guo X, Fan B, Liu Y, et al
    Dimethylation of histone H3 lysine 36 (H3K36me2) as a potential biomarker for glioma diagnosis, grading, and prognosis.
    J Neuropathol Exp Neurol. 2023 Mar 15:nlad016. doi: 10.1093.
    PubMed     Abstract available


  97. BRANDEL MG, Goodwill VS, Park A, Snyder V, et al
    Sudden unexpected death from hydrocephalus due to cerebellopontine angle meningioma.
    J Neuropathol Exp Neurol. 2023 Mar 2:nlad014. doi: 10.1093.
    PubMed    


    February 2023
  98. GUBBIOTTI MA, Santi M, Storm PB, Li M, et al
    First-time identification of a KIF5B-NTRK2 fusion in extraventricular neurocytoma.
    J Neuropathol Exp Neurol. 2023;82:272-275.
    PubMed    


  99. KLEINSCHMIDT-DEMASTERS BK, Ormond DR
    Leptomeningeal metastases and dural spread in adult high-grade astrocytomas.
    J Neuropathol Exp Neurol. 2023;82:194-201.
    PubMed     Abstract available


  100. KANG MK, Ahn SJ, Ha J, Park SH, et al
    Natural killer T-cell primary CNS lymphoma presenting as lymphomatosis cerebri: a case report and literature review.
    J Neuropathol Exp Neurol. 2023;82:261-266.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum